• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Scilex Holding Company

    1/6/26 6:02:24 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SCLX alert in real time by email
    RW 1 d942297drw.htm RW RW

    Scilex Holding Company

    960 San Antonio Road

    Palo Alto, CA 94303

    VIA EDGAR

    January 6, 2026

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

    Office of Life Sciences

    100 F Street, N.E.

    Washington, DC 20549-0406

     

      Re:

    Scilex Holding Company (the “Registrant”)

    Request to Withdraw Registration Statement on Form S-1

    File No. 333-289223

    Ladies and Gentlemen:

    In accordance with Rule 477(a) of the Securities Act of 1933, as amended (the “Securities Act”), the Registrant hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Registration Statement on Form S-1 (File No. 333-289223) of the Registrant, together with all exhibits and amendments thereto (collectively, the “Registration Statement”), effective as of the date hereof or as soon as practicable thereafter.

    The Registration Statement has not been declared effective and no securities covered by the Registration Statement have been issued or sold. The Registrant has decided not to pursue the sale of securities for which the Registration Statement was filed. Based on the foregoing, the Registrant submits that the withdrawal of the Registration Statement is consistent with the public interest and protection of investors.

    Pursuant to Rule 477(b), the Registrant understands that this request for withdrawal of the Registration Statement will be deemed granted as of the date hereof unless the Registrant receives notice from the Commission within 15 days of the date hereof that such request will not be granted.

    The Registrant acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. The Registrant, however, requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Registrant’s account, to be offset against the filing fee for any future registration statement the Registrant may file with the Commission.

    Upon the granting of the Commission’s consent, please send copies of the order withdrawing the Registration Statement to the undersigned at Scilex Holding Company, 960 San Antonio Road, Palo Alto, California, Attention: Chief Executive Officer & President, and to the Registrant’s legal counsel, Paul Hastings LLP, 1117 S. California Avenue, Palo Alto, California 94304, Attn: Elizabeth Razzano.

    Please do not hesitate to contact Elizabeth Razzano of Paul Hastings LLP, counsel to the Registrant, at (650) 320-1895 with any questions with regard to this matter.

     

    Sincerely,

     

    SCILEX HOLDING COMPANY

    By:   /s/ Henry Ji
      Henry Ji, Ph.D.
      Chief Executive Officer and President

     

    cc:

    Jeffrey T. Hartlin, Paul Hastings LLP

    Elizabeth A. Razzano, Paul Hastings LLP

    Get the next $SCLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCLX

    DatePrice TargetRatingAnalyst
    1/27/2025$22.00Buy
    D. Boral Capital
    10/16/2024$14.00Buy
    Alliance Global Partners
    6/13/2024$13.00Buy
    Rodman & Renshaw
    10/16/2023$4.00Buy
    B. Riley Securities
    10/13/2023$4.00Buy
    B. Riley Securities
    10/9/2023$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $SCLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Scilex Holding Co sold $18,176,455 worth of shares (14,713,490 units at $1.24), decreasing direct ownership by 6% to 229,731,770 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Reporting)

    1/8/26 6:44:48 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Large owner Scilex Holding Co sold $12,771,580 worth of shares (20,657,300 units at $0.62), decreasing direct ownership by 8% to 244,445,260 units (SEC Form 4)

    4/A - Scilex Holding Co (0001820190) (Reporting)

    12/31/25 8:50:51 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Scilex Holding Co sold $12,771,580 worth of shares (20,657,300 units at $0.62), decreasing direct ownership by 8% to 244,445,260 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Reporting)

    12/30/25 8:24:02 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Scilex Holding Company

    SCHEDULE 13D/A - Scilex Holding Co (0001820190) (Filed by)

    1/8/26 7:49:20 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form RW filed by Scilex Holding Company

    RW - Scilex Holding Co (0001820190) (Filer)

    1/6/26 6:02:24 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Scilex Holding Company

    SCHEDULE 13D/A - Scilex Holding Co (0001820190) (Filed by)

    12/31/25 8:54:42 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    12/18/24 7:04:41 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/31/24 12:44:57 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/29/24 6:59:31 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.

    PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced confirmed Dream Bowl 2026 Meme Coins claim process on December 24, 2025. Powered by Datavault AI's patented, encrypted blockchain infrastructure and real-world asset (RWA) tokenization technologies, the Dream Bowl 2026 Meme Coin represents a pioneering fusion of sports, digital assets, and shareholder perks. Eligible shareholders of record a

    12/23/25 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Inc. (NASDAQ: DVLT) Announces a Distribution Date of Dec. 24, 2025, for the Dream Bowl Meme Coin Tokens to All Eligible Record Equity Holders of Datavault AI and Holders of Common Stock of Scilex Holding Company

    PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the "Datavault Board") has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the "Meme Coin") to all eligible record equityholders of Datavault AI.  Dec. 24, 2025, will also be the distribution date for Datavault AI's voluntary distribution of Meme Coins to record holders of common stock of Scilex Holding Company (NASDAQ:SCLX), which is being made as a token of Datavault AI's appreciation for Scilex's relat

    12/11/25 4:05:00 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Scilex Holding with a new price target

    D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

    1/27/25 8:08:33 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on Scilex Holding with a new price target

    Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

    10/16/24 8:01:57 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

    Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

    6/13/24 7:16:15 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Leadership Updates

    Live Leadership Updates

    View All

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

    7/23/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

    PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr

    3/4/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Financials

    Live finance-specific insights

    View All

    Datavault AI Inc. (NASDAQ: DVLT) Announces a Distribution Date of Dec. 24, 2025, for the Dream Bowl Meme Coin Tokens to All Eligible Record Equity Holders of Datavault AI and Holders of Common Stock of Scilex Holding Company

    PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the "Datavault Board") has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the "Meme Coin") to all eligible record equityholders of Datavault AI.  Dec. 24, 2025, will also be the distribution date for Datavault AI's voluntary distribution of Meme Coins to record holders of common stock of Scilex Holding Company (NASDAQ:SCLX), which is being made as a token of Datavault AI's appreciation for Scilex's relat

    12/11/25 4:05:00 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

    PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex's relationship with Datavault AI as a stockholder of Datavault A

    11/21/25 3:59:33 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin

    PHILADELPHIA, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, announced today that, in connection with its previously announced distribution of Dream Bowl 2026 Meme Coins to eligible record equity holders of Datavault AI, Nasdaq has informed the Company that it is not expecting to quote an ex-dividend date for such distribution and therefore eligible record equity holders of Datavault AI must be holders as of the record date of November 25, 2025 in order to receive the distribution.  With respect to Datavault AI's volunta

    11/21/25 3:56:48 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    4/25/24 5:25:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    3/5/24 4:22:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care